Insider Transactions and Holdings
-
Entity Type
-
Company
-
Role
-
Director
-
Stock Symbol
-
SYRE on Nasdaq
There are no Buy or Sell transactions made by Fairmount Funds Management LLC since 11/21/2023
Holdings reported by Fairmount Funds Management LLC for Spyre Therapeutics, Inc.
| Class |
Num Shares |
Value |
Price $ |
Transaction Date |
Ownership |
Underlying Class |
Underlying Amount |
| Common Stock |
4.02M |
$2.85M |
$0.71 |
Apr 25, 2024 |
By Fairmount Healthcare Fund II L.P. |
|
|
| Common Stock |
406K |
$288K |
$0.71 |
Apr 25, 2024 |
By Peter Harwin |
|
|
| Common Stock |
406K |
$288K |
$0.71 |
Apr 25, 2024 |
By Tomas Kiselak |
|
|
| Series A Preferred Stock |
346K |
|
|
Apr 25, 2024 |
By Fairmount Healthcare Fund II L.P. |
Common Stock |
17.5M |
| Series B Preferred Stock |
16.7K |
|
|
Dec 29, 2023 |
By Fairmount Healthcare Fund II L.P. |
Common Stock |
667K |
| Stock Option (Right to Buy) |
11.3K |
|
|
May 14, 2024 |
By Peter Harwin |
Common Stock |
|
| Stock Option (Right to Buy) |
11.3K |
|
|
May 14, 2024 |
By Tomas Kiselak |
Common Stock |
|
Transactions reported by Fairmount Funds Management LLC for Spyre Therapeutics, Inc.
| Sym |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares After |
Date |
Ownership |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.